Published in Cancer Chemother Pharmacol on January 01, 1991
Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech (2009) 0.91
Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine (2014) 0.84
A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model. Arch Otolaryngol Head Neck Surg (2012) 0.77
A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model. Otolaryngol Head Neck Surg (2014) 0.76
Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget (2017) 0.75
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst (2000) 4.15
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A (1997) 3.20
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A (1997) 2.91
A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry (1985) 2.72
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol (1997) 2.23
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Is there a future for neutron capture therapy? Int J Radiat Oncol Biol Phys (1996) 2.08
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A (1995) 2.00
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res (1996) 1.95
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr (1992) 1.89
Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.83
Risk factors in breast-conservation therapy. J Clin Oncol (1994) 1.82
Demonstration of radiosensitization of hypoxic cells in solid tumours by metronidazole. Br J Radiol (1974) 1.77
Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol (2000) 1.76
Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci (1982) 1.67
EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys (1995) 1.59
EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol (1995) 1.58
The impact of treatment time and smoking on local control and complications in T1 glottic cancer. Int J Radiat Oncol Biol Phys (1998) 1.57
Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol (1998) 1.55
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol (2000) 1.53
Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry (1995) 1.47
Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer (1988) 1.44
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol (2001) 1.43
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer (2005) 1.40
Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1996) 1.40
[Radiotherapy of the neck as a risk factor for stroke]. Ned Tijdschr Geneeskd (2005) 1.38
[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation]. Ned Tijdschr Geneeskd (1996) 1.38
[A solitary sternal lesion found by skeletal scintigraphy following treatment for breast carcinoma]. Ned Tijdschr Geneeskd (2007) 1.38
Plea for a preoperative adjuvant approach in the management of rectal cancer. Int J Radiat Oncol Biol Phys (1994) 1.38
The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys (1990) 1.37
Radiation-induced apoptosis. Cell Tissue Res (2000) 1.36
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer (2000) 1.31
Psychological effects of breast conserving therapy in comparison with radical mastectomy. Int J Radiat Oncol Biol Phys (1985) 1.31
Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol (1989) 1.30
Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol (1997) 1.29
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther (2006) 1.27
Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs (1996) 1.27
The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol Biol Phys (1997) 1.26
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer (2003) 1.22
Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest (1999) 1.21
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst (1996) 1.21
Hypoxia in head and neck cancer: how much, how important? Head Neck (2005) 1.20
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1999) 1.18
Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res (1999) 1.18
High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol (2003) 1.17
Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Cancer Res (1980) 1.16
Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys (2000) 1.13
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res (1999) 1.12
Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations. Radiother Oncol (1988) 1.12
Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol (2000) 1.12
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl (1995) 1.11
Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol (2005) 1.10
Biological properties and response to x-rays of first-generation transplants of spontaneous mammary carcinomas in C3H mice. Int J Radiat Biol Relat Stud Phys Chem Med (1975) 1.09
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1999) 1.08
The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci (1997) 1.07
Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus (2004) 1.06
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer (1997) 1.06
The incidence of lung metastases in C3H mice after treatment of implanted solid tumours with x-rays or surgery. Br J Cancer (1974) 1.05
The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol (1999) 1.05
Evaluation of breast conserving therapy: clinical, methodological and psychosocial perspectives. Eur J Surg Oncol (1988) 1.04
The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat (2008) 1.02
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl (1995) 1.01
Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci (2000) 1.01
A verification procedure to improve patient set-up accuracy using portal images. Radiother Oncol (1993) 1.01
Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer (2002) 1.00
The clinical status of Tpot as a predictor? Or why no tempest in the Tpot! Int J Radiat Oncol Biol Phys (1995) 0.99
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res (1998) 0.99
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer (1998) 0.99
Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer (2003) 0.99
Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer (2008) 0.98
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Lab Anim (2003) 0.98
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl (1996) 0.98
Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs (1998) 0.97
Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma. Radiother Oncol (1991) 0.97
Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1998) 0.96
Analysis of growth delay data: potential pitfalls. Br J Cancer Suppl (1980) 0.96
Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy. Radiother Oncol (1994) 0.95
Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. J Natl Cancer Inst (2004) 0.95
The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol (1994) 0.95
Defective repair of DNA double-strand breaks and chromosome damage in fibroblasts from a radiosensitive leukemia patient. Cancer Res (1995) 0.95
Dose and volume effects on fibrosis after breast conservation therapy. Int J Radiat Oncol Biol Phys (1994) 0.95
Modification of stromal radiosensitivity by misonidazole and WR-2721. Br J Radiol (1983) 0.95
Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene (2012) 0.94
The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos (2000) 0.94
Optimum fractionation in X-ray treatment of C3H mouse mammary tumours. Br J Radiol (1974) 0.93
The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother (2008) 0.93
The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat (2009) 0.93
Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer (2000) 0.93
Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res (1990) 0.93
Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys (1998) 0.93
Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer (2012) 0.92